News

PipelineReview.com3h
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
BALA CYNWYD, PA, USA I July 08, 2025 I Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing ...
PipelineReview.com17h
Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL
ROCKVILLE, MD, USA and SUZHOU, China I July 10, 2025 I Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing ...
PipelineReview.com17h
Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody
MIDDLETOWN, DE, USA I July 10, 2025 I Earendil Labs, an AI-empowered biotechnology company, announced that it has completed cohort 1 dosing in a phase 1 trial ...
PipelineReview.com17h
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival ...
PipelineReview.com17h
Eolas Therapeutics Secures Full Development Rights to AZD4041
PALM BEACH GARDENS, FL, USA I July 10, 2025 I Eolas Therapeutics today announced that it has entered into a new agreement with AstraZeneca to assume full development rights to AZD4041, an ...